SBIR-STTR Award

Gesture Based Medication Adherence Confirmation For Clinical Trials
Award last edited on: 7/29/13

Sponsored Program
SBIR
Awarding Agency
NIH : NCRR
Total Award Amount
$273,165
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Adam Hanina

Company Information

Ai Cure Technologies Inc (AKA: Aicure LLC)

122 West 27th 10th Floor
New York, NY 10001
   (646) 723-1260
   N/A
   www.aicuretechnologies.com
Location: Single
Congr. District: 12
County: New York

Phase I

Contract Number: 1R43RR032224-01A1
Start Date: 9/6/11    Completed: 3/5/12
Phase I year
2011
Phase I Amount
$273,165
Ai Cure Technologies LLC, was established in 2009 to develop webcam software solutions for mobile devices and other computing platforms that automate and reduce the cost of monitoring patient behavior and medication adherence. Poor medication adherence is one of the healthcare system's greatest challenges. More than two million serious adverse events and about 100,000 deaths occur annually due to this problem. Total US healthcare costs of drug-related morbidity, including poor adherence, are estimated at $290 billion per year. In clinical trials, adherence levels for populations with chronic conditions range from 43% to 78%, the high cost of clinical trials being partly attributable to inefficiencies created by poor adherence. As clinical trials become larger, and more move outside the US, tracking patient behavior becomes more difficult, as does the burden on the FDA to monitor these sites. Traditional monitoring methods such as pill counting, patient interviews, and blood work have proven unreliable. Indeed, a recent clinical trial employing these traditional monitoring methods was confirmed to have failed for poor medication adherence. Products such as smart blister packs and MEMS caps are costly and do not confirm medication has been taken. Direct observation therapy is effective to confirm medication adherence;but is labor-intensive, patient intrusive, and expensive. Ai Cure Technologies will provide a webcam software solution for distribution by clinical trial sponsors to automate direct observation of medication administration and provide an audit trail of medication adherence. The solution will provide reliable data to the research community and policy-makers to improve overall health outcomes and rein in soaring costs. The solution will also act as a tool for the FDA to better regulate trials before drugs come to market.

Public Health Relevance:
In clinical trials, whether or not participants take their prescribed medication and to what degree is neither well understood nor reliably monitored through existing and antiquated methods such as pill counting or patient interviews. This means that it is difficult to provide an accurate assessment on drug efficacy or safety within a prescribed regimen and over the course of a clinical trial. AiView will provide a system for automatically determining medication adherence of clinical trial patients, and allow access to this data by clinical trial managers.

Thesaurus Terms:
Address;Adherence;Adherence (Attribute);Attention;Behavior;Biomedical Research;Bleb;Blister;Blood;Blood Reticuloendothelial System;Buccal Cavity;Buccal Cavity Head And Neck;Bulla;Bullous Lesion;Caring;Cavitas Oris;Cessation Of Life;Chronic;Clinical Trials;Communities;Computer Software;Controlled Environment;Data;Death;Devices;Disease;Disorder;Drugs;Electronics;Face;Gestures;Goals;Health;Health Care Costs;Health Care Systems;Health Costs;Healthcare Costs;Healthcare Systems;Human;Hypertension;Incentives;Instruction;Intervention;Intervention Strategies;Interview;Loinc Axis 4 System;Link;Man (Taxonomy);Marketing;Measures;Medical;Medication;Medication Systems;Medicine;Methods;Modern Man;Monitor;Morbidity;Morbidity - Disease Rate;Mouth;Movement;New York;Oral Cavity;Outcome;Participant;Patient Care;Patient Care Delivery;Patient Education;Patient Instruction;Patient Monitoring;Patient Self-Report;Patient Training;Patients;Performance;Pharmaceutic Preparations;Pharmaceutical Agent;Pharmaceutical Preparations;Pharmaceuticals;Pharmacologic Substance;Pharmacological Substance;Phase;Pill;Policy Maker;Population;Privacy;Protocol;Protocols Documentation;Provider;Regimen;Reliance;Research;Risk;Sbir;Sbirs (R43/44);Safety;Security;Self Administration;Self-Report;Sensitivity And Specificity;Series;Serious Adverse Event;Site;Small Business Innovation Research;Small Business Innovation Research Grant;Software;Solutions;Staging;Supervision;System;Systems Analyses;Systems Analysis;Technology;Testing;Time;Vascular Hypertensive Disease;Vascular Hypertensive Disorder;Vesication;Work;Artificial Environment;Base;Behavior Observation;Behavioral Observation;Body Movement;Clinical Investigation;Commercial Application;Computer Program/Software;Cost;Diaries;Disease/Disorder;Drug Efficacy;Drug/Agent;Faces;Facial;High Blood Pressure;Hyperpiesia;Hyperpiesis;Hypertensive Disease;Improved;Inducement;Interventional Strategy;Laptop;Medication Adherence;Medication Compliance;Patient Population;Pill (Pharmacologic);Population Health;Success;Tool;Trend;Usability

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----